A Phase I, Open-Label, Four-Part, Single-Sequence Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
Latest Information Update: 26 Apr 2023
At a glance
- Drugs Dersimelagon (Primary)
- Indications Autoimmune disorders; Diffuse scleroderma; Erythropoietic protoporphyria
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma America
- 10 Feb 2022 Status changed from recruiting to completed.
- 22 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Jan 2022.
- 22 Dec 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2022.